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pMell7 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and 
HMB-50 and by anti-melanoma CTL
GJ Adema, ABH Bakker, AJ de Boer, P Hohenstein and CG Figdor
Department o f  Tumour Immunology, University Hospital Nijmegen St. Radboud, Philips van Leydenlaan 25, 6525 EX Nijmegen, 
The Netherlands.
Summary Recently, we cloned the cDNA encoding the melanocyte lineage-specific antigen gplOO and 
demonstrated that gplOO is recognised by three different monoclonal antibodies (MAbs) used to diagnose 
malignant melanoma. In addition, we showed that tumour-infiltrating lymphocytes (TIL 1200) from a 
melanoma patient reacted specifically with cells transfected with the gplOO cDNA. Molecular characterisation 
of the gplOO cDNA revealed that the gplOO antigen is highly homologous, but not identical, to another 
melanocyte-specific protein, pMel!7. Here, we report that cells transfected with pMell7 cDNA also react with 
all three MAbs used to diagnose malignant melanoma, NKI-beteb, HMB-45 and HMB-50, Moreover, pMell7 
transfectants are specifically lysed by TIL 1200. These data demonstrate that antigenic processing of both gplOO 
and pMell7 give rise to peptides seen by anti-melanoma cytotoxic T lymphocytes (CTL) and are therefore 
potential targets for immunotherapy of malignant melanoma.
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Melanoma is a neoplasm that originates from melanocytes, 
pigment-producing cells in the skin. Melanoma is a relatively
recognised by all three MAbs used to diagnose malignant 
melanoma and is properly processed and presented to anti-
immunogenic tumour, as demonstrated by the presence of melanoma tumour-infiltrating lymphocytes, 
both cytotoxic T lymphocytes (CTLs) and antibodies (Mattes 
et al., 1983; Knuth et al., 1992) in melanoma patients that 
react with melanoma tumour cells. The availability of 
antibodies and CTLs with anti-melanoma reactivity allowed 
the identification of several tumour-associated antigens.
These include tumour-specific antigens and melanocyte 
differentiation antigens that are expressed by melanoma 
tumour cells as well as by normal melanocytes and retina 
(van der Bruggen et al., 1991; Brichard et al., 1993;
Vijayasaradhi et al., 1990; Bakker et al., 1994; Kawakami 
et al., 1994a,b; Coulie et al., 1994; Gaugler et al., 1994 and 
Wang et al., 1995). Identification of the antigens recognised 
by anti-tumour CTL is important for understanding the 
molecular basis of tumour recognition by T cells and may 
lead to the development of new immunotherapeutical 
strategies to treat cancer patients.
Recently, we cloned the cDNA encoding the melanocyte 
differentiation antigen gplOO and demonstrated that it is
by three different MAbs used to diagnose 
malignant melanoma, NKI-beteb, HMB-50 and HMB-45
M aterials and methods
Cells and monoclonal antibodies
Culturing of the melanoma cell lines MEWO, BLM and of 
COS-7 cells has been described previously (Adema et al., 
1993; 1994). TIL 1200 was generated from a metastatic 
melanoma and cultured with 1000 U ml 1 interleukin-2 (IL- 
2) (Cetus Corp., Emeryville, CA, USA) as described 
previously (Kawakami et al., 1992). NKI-beteb and HMB- 
50 have been described previously (Vennegoor et a l,  1988; 
Vogel and Esclamado, 1988). HMB-45 was purchased from 
Enzo Biochem.
Molecular cloning and nucleotide sequence analysis
Using a reverse transcriptase-polymerase chain reaction
, the Netherlands)(PCR) (GeneAmp kit, Perkin
approach with 5'-ctgcatggagatcttcatcg-3' as the 5' primer 
(Adema et al., 1993, 1994). In addition, we demonstrated that and 5'-ttctgtgagctccaggaaaatcacagcat-3' as the 3' primer we 
gplOO is recognised by a tumour-infiltrating T-cell line (TIL isolated the 3' part of pMell7 cDNA from total RNA
isolated from the melanoma cell line MEWO. The PCR 
product was used to replace the 3' part of the gplOO cDNA 
as present in pSVLgpl00+ (Adema et a l ,  1994) using Bglll
1200), isolated from a melanoma patient (Bakker et al.,
1994). Molecular characterisation of the cDNA encoding 
gplOO revealed that it is a type I transmembrane glycoprotein 
of 641 amino acids highly homologous to another and the newly created Sacl site in the 3' primer (underlined).
melanocyte-specific protein, pMell7 (Adema et al., 1994; 
Kwon et al., 1991). Nucleotide sequence analysis of genomic 
DNA indicated that the transcripts corresponding to gplOO
and pMell7 cDNAs originate from a single gene via 
alternative splicing. The difference between gplOO and 
pMell7 consists of a stretch of seven amino acids in the 
carboxy terminal part of pMell7 (position 567; Adema et al., 
1994) that is absent in gplOO. In all normal and malignant 
melanocytic cells expressing the gpl00/pMell7 gene, gplOO 
and pMe!17 mRNAs are expressed simultaneously.
Here, we demonstrate that pMell7, like gplOO, is
The resulting construct, pSVLpMell7, was sequenced by the 
dideoxy-nucleotide sequencing method using T7 DNA 
polymerase (Pharmacia, Woerden, The Netherlands). 
pCMVneopMell7 was constructed by cloning the complete 
pMell7 cDNA from pSVLpMell7 as a blunt-ended XbaI -  
Sacl fragment in the blunt-ended BamHI site of PCMVneo 
(Bakker et al., 1994).
Transfections and immunostaining
Transient expression of DNA constructs in COS-7 cells was 
performed using 40 fig ml- 1 lipofectin reagent (BRL, 
Gaithersbure. MD. USA) and 7.5 ue of DNA. BLM cells
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were transfected with 20 fig of pCMVneopMell7 DNA using 
calcium phosphate transfection systems (BRL, Gaithersburg, 
MD, USA) and stable clones were isolated by G418 selection 
(1 mg ml-1) as previously described (Bakker et al., 1994).
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T ranslected were prepared for immunofluorescence
using FITC-conjugated GAM-IgG-F(ab ')2
Francisco, CA, USA) as
(Zymed, San 
(Adema et
ai, 1993) and examined using confocal laser scanning 
microscope at 488 nm (Biorad MRC 600).
Metabolic labelling and immunoprécipitations
Immunoprécipitation experiments were performed on 
metabolically labelled (L-[35S]methionine/cysteine; Amer-
sham) cells as described by Vennegoor et al. (1988) 
either NKI-beteb or HMB-50 covalently linked to 
A-CL 4B arose beads (Pharmacia,
Tfc tV*Netherlands). Immunoprecipitates were
by SDS PAGE using 5-17.5%
gradient gels. The relative molecular weight o f  the 
was determined using eo-electrophorised, prestained markers 
(BRL, Gaithersburg, MD, USA).
1 M sodium  s.
(Kodak XAR).
were treated with 
ate (pH 5.4) before autoradiography
as described
Cluomium-release assav
Chromium release assays were 
previously (Bakker et al., 1994). Briefly, 10“ target cells 
were incubated with 100 /(Ci [slCr]sodium chromate (Amer- 
sham, Bucks, UK) for 1 h. Various amounts o f effector cells 
were then added to 2 x 103 target cells in triplicate wells o f U- 
bottomed microtitre plates (Costar, Badhoevedorp, The 
Netherlands) in a final volume of 150 jttl. After 5 h of 
incubation part of the supernatant was harvested and its 
radioactive content was measured.
Results
a
The gpl()0/pMell7 gene encodes both gplOO and pM ell7  
mRNA as a consequence of alternative RNA processing. The 
pMell7 mRNA encodes a stretch of seven amino acids not 
encoded by the gplOO mRNA (Figure I). To investigate the 
immunological properties o f pM ell7 we 
pMell7 cDNA. Using an RT-PCR approach we iirsl cloned 
the 3' part of the pMell7 cD N A  encoding the carboxy 
terminal part of pMell7, including the additional seven 
amino acids absent in gplOO. Nucleotide sequence analysis o f  
the 3' part confirmed the presence of the nucleotide sequence
LLTGQI'iAi >1 
ILLTGQl'IAGI 
GILLTt ìQI'IA 
IM PV PG ILL 
ÇHJ MPVPGIL 
Q ! 11M P VPG X
Î E L 1  7 A V V STQ J'.i.IM PV PG ILLTG O EA G I.iG Q V Pl - J
G  P I  0  0 A V V S T Q L IM PG Q EA G LG Q V Pi
Q LIM PG Q EA
L IM P G Q E A G L
IMPGOEAGL
Figure 1
A2.1 binding
s unique in pMell7 and gplOO that lit the HLA- 
ifs [Falk et al. (1991), Drijfliout el al.
The pMe!17 specific amino acids are indicated in bold.
a b
c d
Figure 2 MAbs NKI-beteb, HMB-45 and HMB-50 recognise pMell7. BLM cells transfected with PSVLpMell7 were analysed lor 
reactivity with NKI-beteb (a), HMB-45 (b), HMB-50 (c) or the secondary antibody (d) respectively. Indirect immunofluorescence 
[FITC-conjugated GAM-IgG-F(ab')2] was examined by confocal laser scanning microscopy. Magnification 60 x .
1046
pMell7 is recognised by anti-melanoma CTL and MAbs
GJ Adema et al
encoding the pMel 17-specific amino acids. In addition, we 
found pMel!7 cDNAs containing either a thymidine (as in 
the gplOO cDNA; Adema et a!., 1994) or a cytosine at 
position 1998. This nucleotide change does not result in an 
amino acid substitution. The finding that the same nucleotide 
difference was found in a gplOO cDNA clone isolated from 
the same cell line, indicates that this particular cell line 
contains two different alleles of the gpl00/pMell7 gene. 
Subsequently, we created a full length pMel!7 cDNA by
NKI-beteb and HMB-50 both specifically detect proteins of 
approximately 100 kDa (95-110 kDa) in extracts of
metabolically labelled COS-7 cells transfected with the 
pMell7 cDNA. The pMeU7 protein co-migrates with the 
gplOO protein immunoprecipitated from COS-7 cells trans­
fected with gplOO cDNA as well as with the proteins 
immunoprecipitated from MEWO melanoma cells. The
slight difference in mobility between transfected COS-7 cells 
and MEWO melanoma cells, which express both gplOO and 
exchanging the 3' part of the gplOO cDNA with the 3' part of pMel!7 endogenously, has previously been shown to be due
pMell7 cDNA.
To investigate whether the difference between gplOO and 
pMell7 affects recognition by the anti-gplOO MAbs NKI-
HMB-45 and HMB-50, we the cDNA
encoding pMell7 into the gp 100/pMel 17 negative melanoma 
cell line BLM. As shown in Figure 2, expression of the
to differential glycosylation (Adema et al., 1994). Collectively, 
these data demonstrate that the difference between gplOO and 
pMell7 does not affect recognition by either of the MAbs 
used to diagnose malignant melanoma, NKI-beteb, HMB-50 
and HMB-45. The data describing the specificity of these 
MAbs for cells of the melanocytic lineage can therefore be
pMell7 cDNA resulted in immunoreactivity with all three extrapolated to the expression of pMell7.
MAbs. The typical speckled staining pattern of the pMell7 
transfectants was identical to that previously observed for
gp 100, that pMell7, like gplOO, localises in
melanosomes. Immunoreactivity with all three MAbs was 
also observed when pMell7 cDNA was transiently expressed 
in non-melanocytic COS-7 cells (data not shown). We also 
analysed the pMell7 protein detected by MAbs NKI-beteb or 
HMB-50 in COS-7 cells transfected with the pMell7 cDNA 
using immunoprécipitations reactions. As shown in Figure 3,
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Previously, we showed that gplOO is by
tumour-infiltrating lymphocytes, (TIL) 1200, isolated from a 
melanoma patient in an HLA-A2.1 manner
(Bakker et al., 1994). To investigate whether the pMell7 
antigen also gives rise to peptide epitopes that gain access to 
the MHC class I presentation pathway, we 
determined the cytolytic activity of TIL 1200 against HLA- 
A2.1 + BLM cells transfected with the pMell7 cDNA. As 
demonstrated in Figure 4, the pMell7 transfectants were 
efficiently lysed by TIL 1200. No specific lysis was observed 
using the parental, untransfected BLM cells or BLM cells 
transfected with the expression vector without an insert (not 
shown). These data demonstrate that peptide epitope(s) 
recognised by TIL 1200 are properly processed from the 
pMell7 protein and presented in the context of HLA-A2.1. 
Two gplOO-derived peptides (corresponding to the amino 
acids at positions 154-162 and 457-466) have been 
identified that are recognised by TIL 1200 (Bakker et cil., 
1995; Kawakami et cil., 1995). These peptides are located in 
the common part between gplOO and pMell7. Since TIL 1200 
is an oligoclonal, CD8 1 T-cell line expressing a 
number of T-cell receptors (Shilyanski et al., 1994), it is most 
likely that either one or both the aforementioned immuno­
genic peptides are responsible for the observed lysis of the 
pMell7 and gplOO transfectants.
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Figure 3 The pMel!7 protein is recognised by NKI-beteb and 
HMB-50 in extracts from pSVLpMe!17 transfected COS-7 cells. 
MEWO cells (MEWO) and COS-7 cells transfected with either 
pSVLpMell7 (pMell7), pSVLgplOO (gplOO) or with a construct 
encoding the gplOO cDNA in the non-coding orientation (Mock) 
were metabolically labelled and subjected to immunoprécipita­
tions using NKI-beteb (NKI), HMB-50 (50) or normal mouse 
serum (NMS) as indicated above each lane. Immunoprecipitated 
proteins were analysed under reducing conditions by SD S-PA G E  
(linear gradient of 5 -17%  acrylamide) and visualised by 
autoradiography. The position and size (kDa) or prestained 
molecular weight markers are indicated.
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Figure 4 Lysis o f HLA-A2.1 +pM ell7  transfectants by TIL 1200. 
BLM cells transfected with pCMVneopMell7, pCMVneogplOO, 
the parental BLM cells and the gpl00/pM ell7 positive Mel624 
cells were tested for sensitivity to lysis by TIL 1200. One 
representative experiment with the stable pMell7 transfected
clone AB1 is shown. BLM; -
gplOO H2.3; -  A - ,  BLM pMell7 AB1.
MeI624; -BLM
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1 MDLVLKRCLLHLAVIGALLAVGATKVPRNQDWLGVSRQLRTKAWNRQLYP
51 EWTEAQRLDCWRGGQVSLKVSNDGPTLIGANASFSIALNFPGSQKVLPDG
101 QVIWVNNTIINGSQVWGGQPVYPQETDDACIFPDGGPCPSGSWSQKRSFV
151 YVWKTWGOYWOVLGG PVS GL SIGTGRAMLGTHTMEVTVYHRRGSRSYVPL
2 01 AHSS SAFTITDOVPFSVSVSOLRALDGGNKHFLRNOPLTFALOLHDPSGY
2 51 LAEADLSYTWDFGDSSGTLISRALWTHTYLEPGPVTAOWLQAAIPLTS
3 01 CGSSPVPGTTDGHRPTAEAPNTTAGQVPTTEWGTTPGQAPTAEPSGTTS
3 51 VQVPTTEV1STAPVQMPTAESTGMTPEKVPVSEVMGTTLAEMSTPEATGM
401 TPAEVSIWLSGTTAAQVTTTEWVETTARELPIPEPEGPDASSIMSTESI
451 TGSLGPLLDGTATLRLVKROVPLDCVLYRYGSFSVTLDIVOGIESAEILO
501 AVPSGEGDAFELTVSCQGGLPKEACMEISSPGCQPPAQRLCQPVLPSPAC
551 QLVLHQILKGGSGTYCLNVSLADTNSLAWSTQLIMPVPGJLLTTGQEAG
60 0 LGQVPLIVGILLVLMAWLASLIYRRRLMKQDFSVPQLPHSSSHWLRLPR
65 0 IFCSCPIGENSPLLSGQQV
Figure 5 Amino acid sequence of the pMell7 antigen (including signal peptide) and location of the peptide epitopes. The peptide 
epitopes as recognised in the gplOO antigen are underlined [Bakker et til. (1995), Kawakami et al. (1995), Cox et til. (1994)]; the 
amino acids uniquely present in pMe!17 are in italic capitals.
Discussion
The data described in this report demonstrate that pMell7, 
like gplOO, is recognised by three MAbs frequently used to 
diagnose melanoma. In addition, we demonstrate that cells 
transfected with pMcll7 cDNA are effectively lysed by anti­
melanoma T cells.
Because of the exclusive reactivity of MAbs NKI-beteb, 
HMB-45 and HMB-50 with cells of the melanocyte lineage, 
they are frequently used to diagnose malignant melanoma
(Ruiter, . The finding that not only gplOO but also
pMell7 reacts with these antibodies emphasises the specific
•ession of both gp 100 and pMell7 in cells of
melanocyte lineage. The identical staining pattern observed 
with the MAbs in gplOO and pMell7 transfectants further
indicates that, like gplOO, pMel!7 is also present in 
melanosomes, which is in line with their proposed role in 
the process of pigmentation (Kwon et al., 1991). Whether
a functional difference between gplOO and 
pMell7 remains to be determined.
The relative immunogenicity of melanoma tumours has 
long been recognised. Both cytotoxic T cells and MAbs have 
been identified that specifically recognise melanoma tumour 
cells. So far, a number of the antigens recognised have been
in detail. They include the tumour-specific 
proteins, MAGE-1 (van der Bruggcn et al., 1991) and 
MAGE-3 (Gaugler et al., 1994), which are expressed in 
different types of tumour cells and in testis. In addition, the 
melanocyte differentiation antigens tyrosinase, gplOO, Melan- 
A/MART-1 and gp75 (Brichard et al., 1993; Bakker et al., 
1994; Kawakami et al., 1994ajr, Coulie et al., 1994; Wang et 
al.,
arto n  t / vri or\
that are expressed in normal and malignant 
melanocytes as well as in retina have been identified as 
targets for anti-melanoma CTLs. Potentially, these antigens 
are targets for specific immunotherapy.
TIL 1200 was isolated from a melanoma metastasis and 
was shown to recognise the melanocyte differentiation 
antigen gplOO. Interestingly, reinfusion of in vitro expanded 
TIL1200 together with IL-2 in the autologous patient resulted 
in objective tumour regression (Kawakami et al., 1994/), 
1995). Here we demonstrate that TIL 1200 not only recognises 
the gplOO antigen, but also the pMell7 antigen that is 
encoded by an mRNA species derived from the same gene via 
alternative splicing. Since we have previously shown that 
melanoma cells express gplOO and pMell7 mRNA simulta­
neously, both proteins contribute to total amount of 
immunogenic peptides presented in the context of IILA-A2. 
t h a t are recon by TIL . This finding is also
consistent with the recent mapping of two peptide epitopes 
(corresponding to the amino acids at positions, 154 162 and 
457 recognised by TIL 1200 in the common part o 
gplOO and pMell.7 (Bakker et a/., 1995; Kawakami et al.,
and Figure 5). it has that
sequence context can affect processing and/or presentation of 
T-cell epitopes (Eisenlohr et al., 1992; Del Val et a/., 1991), 
this does not seem to be the ease for pMell7 and gplOO. The
fact that TIL1200 is an oligoelonal, C T-cell line
expressing a restricted number of T-cell receptors (Shilyan- 
ski et al., 1994), implies that either one or both these epitopes
are properly from the pMell7 antigen and
presented by HLA-A2.I . Attempts to further investigate the 
recognition of the pMell7 epitopes using cloned TIL have 
not been successful.
Besides TIL 1200, other CTL-recognising distinct epitopes 
encoded by the gp 100/pMel 17 have recently been charac­
terised (Cox et al., 1994; Kawakami et al., 1995). A total of 
five distinct peptides have now been identified (Figure 5), all 
of which are present in both gplOO and pMe!17, and are
by the same restriction element, I-ILA-A2.I. 
Examination of the additional amino acid sequence present
1047
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in pMell7 revealed that six peptides (including 9- and 10- 
mers) bearing the HLA-A2.1 binding motif are uniquely
strate that pMell7 is recognised by three different MAbs used 
to diagnose melanoma and functions as a target for anti­
present in pMell7, whereas three peptides are specifically melanoma CTLs. 
present in gplOO (Figure 1). HLA-A2.1 stabilisation 
experiments revealed that two of the pMel 17-specific 
peptides listed in Figure 1 bind to HLA-A2.1 (ABHB and 
GJA unpublished observation). When analysing immunor- 
eactivity against the products of the gpl00/pMell7 gene, one 
should therefore include both gplOO and pMell7.
In conclusion, the data presented in this report demon-
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